The global gout therapeutics market is expected to reach a
value of USD 8.3 billion By 2025, based on a new report by Grand View Research,
Inc. The gout therapeutics market is anticipated to witness significant growth
during the forecast period. This can be attributed to the introduction of major
urate-lowering agents, approval of effective biologics, and increasing number
of patients suffering from chronic gout.
In December 2015, AstraZeneca’s product,
Zurampic (lesinurad), in combination with xanthine oxidase inhibitor (XOI)
received an approval from the U. S. FDA to treat gout. Later in February 2016,
the European Commission approved the drug throughout the European Union (EU).
Hence, introduction of urate-lowering agents is expected to drive the market.
Introduction of biologics to treat gout and
increasing adoption of newer therapies further help propel the industry. For
instance, in March 2013, Novartis received an EU approval for the product,
Ilaris, for use in the treatment of patients suffering from gouty arthritis.
Browse full research report on Gout
Therapeutics Market:
https://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market
Further key
findings from the study suggest:
- Nonsteroidal Anti-inflammatory Agents (NSAIDs)
accounted for the highest share of the market in 2015, which can be
credited to highest penetration, higher demand due to low cost, and
efficient pain relief.
- Urate-lowering agents segment is expected to
grow at the highest rate over the coming years. Expected entry of various
new drugs, increasing adoption of drugs, and growing investment by key
players for development of these agents are likely to drive the segment.
- Chronic gout dominated in 2015 and is expected
to maintain its dominance during the forecast period. Approval of new
drugs to treat chronic gout and long-term expenditure for treatment are
the key factors responsible to propel the industry.
- NSAIDs, colchicine, and corticosteroids are
majorly used to treat acute gout, and urate-lowering agents are utilized
in chronic gout treatment in combination with NSAIDs or Colchicine.
- Geographically, North America dominated the
overall industry in 2015. This is attributed to higher adoption of the
newer & expensive treatments and rising awareness about arthritic
conditions.
- Asia Pacific is expected to witness highest
growth during the forecast period due to growing awareness and increasing
healthcare expenditure. Furthermore, growing investment in the region by key
players is likely to boost the regional growth.
- Some of the key players are Takeda
Pharmaceutical Company Ltd.; Novartis AG; Savient Pharmaceuticals;
AstraZeneca plc; GlaxoSmithKline plc; Merck& Co. Inc.; Teijin Pharma
Ltd.; and Regeneron Pharmaceuticals.
Browse request sample of this report by
Grand View Research:
https://www.grandviewresearch.com/industry-analysis/gout-therapeutics-market/request/rs1
Grand
View Research has segmented the gout therapeutics market by drug class, disease
condition, and region:
Gout
Therapeutics Market Drug Class Outlook (Market Revenue in USD Million, 2014 -
2025)
- NSAIDs
- Corticosteroids
- Colchicine
- Urate-lowering
agents
Gout
Therapeutics Market Disease Condition Outlook (Market Revenue in USD Million,
2014 - 2025)
- Acute Gout
- Chronic Gout
Gout
Therapeutics Regional Outlook (Market Revenue in USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Mexico
- Middle East and
Africa
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment